Funding backs a human-first approach to drug safety and efficacy, reducing reliance on animal testing and accelerating ...
Explore how expanding clinical trials into community and nontraditional sites, simplifying protocols, and leveraging AI can ...
Alzheimer's disease, the most common form of dementia, is responsible for tens of millions of cases around the world. Jens Kalaene/dpa Following tests on apes and mice, a team of University of New ...
In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...
Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...
The U.S. Food and Drug Administration approved an Investigational New Drug (IND) application using efficacy data solely from ...
First study participant dosed in U.S. trial with healthy volunteers and patients with peanut allergy Novel, human-derived, ...
In today’s ACT Brief, we highlight new insights from McKinsey on where AI can meaningfully accelerate clinical development, break down the emerging design and regulatory forces reshaping obesity drug ...
95% of clinical trials fail because animal testing is no substitute for human biology - Vivodyne’s robotics platform grows thousands of human tissues daily, directly tackling the biological gap behind ...
A new study finds just 6% of clinical trials used to approve new drugs in the U.S. reflect the country's racial and ethnic ...
YPrime, a proven leader in clinical trial technology, today announced it has received two distinctions in the 2025 Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback